AIMS: To describe temporal trends in methamphetamine use among young injection drug users (IDU) in San Francisco. DESIGN AND METHODS: Secondary analysis of cross-sectional baseline data collected for a longitudinal study of young IDU from 1998 to 2004. Participants were 1445 young IDU (<30 years old) who reported injection in the previous month, English-speaking, and recruited by street outreach methods. We examined trends for: lifetime (ever) and recent (30-day) methamphetamine use, including injected and non-injected, and by age group and sexual risk behaviour [men who have sex with men injecting drug users (MSM-IDU), male IDU (non-MSM) and female IDU]. RESULTS: In 1998, 1999, 2000, 2001, 2003 and 2004 we interviewed 237, 276, 431, 310, 147 and 44 participants, respectively. Overall, median age was 22 years [interquartile range (IQR) 20-25], 30.3% were women and median duration of injecting was 4.4 years (IQR 2-7). Prevalence of methamphetamine use was high, with 50.1% reporting recent injection, but overall there were no temporal increases in reported 'ever' injected use. Recent methamphetamine injection (past 30 days) increased significantly, and peaked at 60% in 2003. MSM-IDU had higher methamphetamine injection ever (92.3%) and recently (59.5%) compared to heterosexual male (non-MSM) IDU (81.6% and 47.3%, respectively) and to female IDU (78.4% and 46.1%, respectively). CONCLUSIONS: Despite reports of ubiquitous increases in methamphetamine use, there were no significant increases in 6 years in ever injecting methamphetamine overall among young IDU. MSM-IDU who reported the highest methamphetamine use overall reported some increases in recent injected use. The methamphetamine 'epidemic' was probably under way among young IDU earlier than other populations.
AIMS: To describe temporal trends in methamphetamine use among young injection drug users (IDU) in San Francisco. DESIGN AND METHODS: Secondary analysis of cross-sectional baseline data collected for a longitudinal study of young IDU from 1998 to 2004. Participants were 1445 young IDU (<30 years old) who reported injection in the previous month, English-speaking, and recruited by street outreach methods. We examined trends for: lifetime (ever) and recent (30-day) methamphetamine use, including injected and non-injected, and by age group and sexual risk behaviour [men who have sex with men injecting drug users (MSM-IDU), male IDU (non-MSM) and female IDU]. RESULTS: In 1998, 1999, 2000, 2001, 2003 and 2004 we interviewed 237, 276, 431, 310, 147 and 44 participants, respectively. Overall, median age was 22 years [interquartile range (IQR) 20-25], 30.3% were women and median duration of injecting was 4.4 years (IQR 2-7). Prevalence of methamphetamine use was high, with 50.1% reporting recent injection, but overall there were no temporal increases in reported 'ever' injected use. Recent methamphetamine injection (past 30 days) increased significantly, and peaked at 60% in 2003. MSM-IDU had higher methamphetamine injection ever (92.3%) and recently (59.5%) compared to heterosexual male (non-MSM) IDU (81.6% and 47.3%, respectively) and to female IDU (78.4% and 46.1%, respectively). CONCLUSIONS: Despite reports of ubiquitous increases in methamphetamine use, there were no significant increases in 6 years in ever injecting methamphetamine overall among young IDU. MSM-IDU who reported the highest methamphetamine use overall reported some increases in recent injected use. The methamphetamine 'epidemic' was probably under way among young IDU earlier than other populations.
Authors: K Page-Shafer; P J Veugelers; A R Moss; S Strathdee; J M Kaldor; G J van Griensven Journal: Am J Epidemiol Date: 1997-10-01 Impact factor: 4.897
Authors: Gordon Mansergh; David W Purcell; Ron Stall; Mary McFarlane; Salaam Semaan; Jo Valentine; Ronald Valdiserri Journal: Public Health Rep Date: 2006 Mar-Apr Impact factor: 2.792
Authors: William Damon; Ryan McNeil; M-J Milloy; Ekaterina Nosova; Thomas Kerr; Kanna Hayashi Journal: J Public Health (Oxf) Date: 2019-03-01 Impact factor: 2.341
Authors: W Susan Cheng; Richard S Garfein; Shirley J Semple; Steffanie A Strathdee; James K Zians; Thomas L Patterson Journal: J Psychoactive Drugs Date: 2010-03
Authors: M Florencia Etcheverry; Paula J Lum; Jennifer L Evans; Emilia Sanchez; Elisa de Lazzari; Eva Mendez-Arancibia; Ernesto Sierra; José M Gatell; Kimberly Page; Joan Joseph Journal: Vaccine Date: 2011-01-15 Impact factor: 3.641
Authors: Jiang Du; Haiming Sun; David Huang; Haifeng Jiang; Na Zhong; Ding Xu; Yan Zhao; Shuxing Lin; Wenwen Wang; Zheyi Du; Min Zhao; Yih-Ing Hser Journal: Drug Alcohol Depend Date: 2014-07-04 Impact factor: 4.492
Authors: Ricky N Bluthenthal; Daniel Chu; Lynn D Wenger; Philippe Bourgois; Thomas Valente; Alex H Kral Journal: Drug Alcohol Depend Date: 2018-02-15 Impact factor: 4.492
Authors: Melanie L Rusch; Remedios Lozada; Robin A Pollini; Alicia Vera; Thomas L Patterson; Patricia Case; Stefanie A Strathdee Journal: J Urban Health Date: 2009-06-12 Impact factor: 3.671